Spectral AI receives FDA De Novo clearance for DeepView burn diagnostic system

Spectral AI announced FDA De Novo Classification for its DeepView System for burn wound assessment, authorizing commercial distribution in the U.S. The company also secured $31.7 million in BARDA funding and elected its board of directors at its annual stockholder meeting.